Login to Your Account



Other News To Note


Monday, March 19, 2012
• Anthera Pharmaceuticals Inc., of Hayward, Calif., said it cut its headcount by about 45 percent and will reduce or eliminate vendor activities in the wake of the recent termination of the VISTA-16 Phase III trial for futility. The company reported last week that it would cease patient enrollment and dosing in VISTA-16, which was testing sPLA2 inhibitor varespladib in acute coronary syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription